Addex Therapeutics Statistics
Total Valuation
ADXN has a market cap or net worth of $6.88 million. The enterprise value is $4.16 million.
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADXN has 116.57 million shares outstanding. The number of shares has increased by 7.75% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 116.57M |
| Shares Change (YoY) | +7.75% |
| Shares Change (QoQ) | +12.09% |
| Owned by Insiders (%) | 19.09% |
| Owned by Institutions (%) | 2.14% |
| Float | 92.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.62 |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.01 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -741.34 |
Financial Efficiency
Return on equity (ROE) is -72.84% and return on invested capital (ROIC) is -18.13%.
| Return on Equity (ROE) | -72.84% |
| Return on Assets (ROA) | -15.90% |
| Return on Invested Capital (ROIC) | -18.13% |
| Return on Capital Employed (ROCE) | -40.30% |
| Weighted Average Cost of Capital (WACC) | 14.46% |
| Revenue Per Employee | $99,412 |
| Profits Per Employee | -$3.82M |
| Employee Count | 2 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.34% in the last 52 weeks. The beta is 1.87, so ADXN's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -20.34% |
| 50-Day Moving Average | 6.84 |
| 200-Day Moving Average | 8.12 |
| Relative Strength Index (RSI) | 47.73 |
| Average Volume (20 Days) | 5,882 |
Short Selling Information
The latest short interest is 7,260, so 0.69% of the outstanding shares have been sold short.
| Short Interest | 7,260 |
| Short Previous Month | 6,748 |
| Short % of Shares Out | 0.69% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.34 |
Income Statement
In the last 12 months, ADXN had revenue of $198,824 and -$7.65 million in losses. Loss per share was -$0.07.
| Revenue | 198,824 |
| Gross Profit | -659,225 |
| Operating Income | -3.11M |
| Pretax Income | -7.77M |
| Net Income | -7.65M |
| EBITDA | -3.08M |
| EBIT | -3.11M |
| Loss Per Share | -$0.07 |
Full Income StatementBalance Sheet
The company has $2.74 million in cash and $45,836 in debt, giving a net cash position of $2.70 million or $0.02 per share.
| Cash & Cash Equivalents | 2.74M |
| Total Debt | 45,836 |
| Net Cash | 2.70M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 7.47M |
| Book Value Per Share | 0.06 |
| Working Capital | 1.49M |
Full Balance SheetCash Flow
| Operating Cash Flow | -1.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 30,551 |
| Net Borrowing | -9,142 |
| Free Cash Flow | -2.00M |
| FCF Per Share | -$0.02 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,564.90% |
| Pretax Margin | -3,909.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |